Published in Drug Week, September 10th, 2004
Guilford plans to conduct the first trial outside the United States as a multi-center, double-blind, placebo-controlled trial evaluating the 30-day efficacy of the single high-dose bolus regimen of Aggrastat compared to placebo in high-risk patients undergoing PCI with coronary stent placement.
The trial is expected to enroll approximately 2000 patients in 100 centers. According to present...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.